Affimed (NASDAQ:AFMD) Receives $7.90 Average Price Target from Analysts

Shares of Affimed (NASDAQ:AFMD) have been given an average rating of “Hold” by the seven ratings firms that are currently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $7.90.

Several research analysts recently commented on the company. Wells Fargo & Company reissued an “equal weight” rating and set a $0.10 price target (down from $11.00) on shares of Affimed in a research report on Tuesday, May 13th. Wall Street Zen began coverage on shares of Affimed in a research note on Monday, May 19th. They issued a “sell” rating for the company. Leerink Partners restated a “market perform” rating and set a $0.39 price objective (down from $5.00) on shares of Affimed in a research note on Tuesday, May 13th. Cantor Fitzgerald downgraded shares of Affimed from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 14th. Finally, Leerink Partnrs cut Affimed from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 13th.

Affimed Stock Down 34.9%

Shares of NASDAQ AFMD opened at $0.18 on Wednesday. The company has a fifty day moving average price of $0.66 and a 200 day moving average price of $1.30. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13. Affimed has a 1-year low of $0.07 and a 1-year high of $8.95.

Hedge Funds Weigh In On Affimed

An institutional investor recently bought a new position in Affimed stock. Northern Trust Corp bought a new position in shares of Affimed (NASDAQ:AFMD) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 183,118 shares of the biopharmaceutical company’s stock, valued at approximately $218,000. Northern Trust Corp owned approximately 1.14% of Affimed as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.